AOD 9604 Dosage Protocol: What Research Use Looks Like

AOD 9604 is a synthetic peptide fragment of human growth hormone (HGH) made up of amino acids 176–191. The most commonly cited AOD 9604 dosage protocol in research settings is 300 mcg injected subcutaneously once daily, often split into two 150 mcg doses, for 8 to 12 weeks. AOD 9604 is not FDA-approved for human use, and no official clinical dose exists.

The details below describe laboratory and self-reported research use only. They are not medical advice.

What Is AOD 9604?

AOD 9604, also written AOD-9604 or HGH 176–191, is a modified piece of the growth hormone molecule. Researchers designed it to isolate the region associated with fat metabolism while removing the parts linked to growth and blood sugar effects.

Early animal and human trials explored whether the peptide could support lipolysis, the breakdown of stored fat. Results were mixed, and the compound never received regulatory approval for weight management.

AOD 9604 is a research chemical that is not approved by the FDA for treating obesity or any other medical condition.

Typical AOD 9604 Dosage Protocol in Research

Reported amounts vary widely between labs, forums, and vendors. A commonly referenced middle ground is 300 mcg per day, but lower and higher figures appear in user logs.

Daily dose	Frequency	Typical context	Notes
100–200 mcg	Once daily	Low-dose or first-time research	Often used to gauge tolerance
300 mcg	Once daily, or 150 mcg twice daily	Most frequently cited protocol	Middle of the reported range
500 mcg	Once or twice daily	Higher-dose self-reports	Little controlled human data

Because there is no standardized dose, two people following a "300 mcg protocol" may be using very different products and injection schedules.

Converting a 5 mg Vial into Daily Doses

Many lab protocols start with an aod-9604 5mg dosage reconstituted in 1 to 2 mL of bacteriostatic water, which makes small draws easier to measure accurately.

• 5 mg vial + 1 mL water = 5,000 mcg per mL, so 300 mcg is about 0.06 mL.
• 5 mg vial + 2 mL water = 2,500 mcg per mL, so 300 mcg is about 0.12 mL.
• Insulin syringes marked in units make these small volumes easier to draw.

When and How Often to Take AOD 9604

The most common answer to how often do you take aod 9604 is once per day. Some protocols divide the total into two smaller injections, usually morning and evening.

Timing is debated more than dose. The most frequently reported approach is a morning injection on an empty stomach, roughly 30 minutes before eating or training.

• Morning, fasted: most commonly reported in user logs.
• Pre-workout: often chosen by people pairing the peptide with exercise.
• Before bed: less common, sometimes used to mimic natural nighttime HGH pulses.

AOD 9604 has a short reported half-life, so consistent daily timing matters more than the exact hour chosen.

AOD 9604 Cycle Length and Stacking

A typical aod 9604 cycle length runs 8 to 12 weeks, followed by a break of at least 4 weeks. Shorter 4- to 6-week runs are reported, but they may not be long enough to observe meaningful changes.

Some researchers stack AOD 9604 with other metabolic peptides, while others run it alone to avoid confusing results. Researchers comparing metabolic peptides often ask about aod 9604 vs mots-c, since both are studied for energy metabolism through very different mechanisms.

Feature	AOD 9604	MOTS-c
Origin	HGH fragment 176–191	Mitochondrial-derived peptide
Main research focus	Lipolysis and fat metabolism	Metabolic regulation and insulin sensitivity
Commonly reported dose	300 mcg daily	5–10 mg per week, split
Reported half-life	Short, roughly 30 minutes	Not well established
FDA status	Not approved for human use	Not approved for human use

Reconstitution and Handling

AOD 9604 usually arrives as a lyophilized powder that must be mixed with bacteriostatic water before use. Add the water slowly down the inside wall of the vial instead of spraying it directly onto the powder.

Cloudy, thick, or stringy solutions — sometimes described as aod-9604 gelling up — often point to poor reconstitution, contamination, or a degraded peptide. Those vials should be discarded rather than injected.

• Store unreconstituted powder in the freezer, away from light.
• Keep reconstituted vials refrigerated at 2–8 °C and use them within a few weeks.
• Swirl gently; never shake the vial vigorously.
• Use sterile technique and a fresh needle for every draw.

Safety, Side Effects, and Legal Status

AOD 9604 is not FDA-approved for human use in the United States, and it is sold as a research chemical. Purity, sterility, and actual peptide content are not regulated the way prescription medications are.

In early human studies, reported side effects were generally mild and included headache, nausea, and injection-site irritation. Long-term safety data in humans remains limited.

Anyone considering AOD 9604 should discuss it with a licensed healthcare professional first, especially if they take other medications or have a medical condition. This article is informational and is not a substitute for medical advice.

COMMON QUESTIONS

Frequently Asked Questions

How much AOD 9604 do people typically use per day?

Most research and self-reported protocols cite 300 mcg injected subcutaneously once daily, sometimes split into two 150 mcg doses. Some users report lower amounts around 100–200 mcg, while others go up to 500 mcg. There is no officially recognized clinical dose because AOD 9604 is not FDA-approved for human use.

How long can you run an AOD 9604 cycle?

A typical reported cycle lasts 8 to 12 weeks, followed by a break of at least 4 weeks. Shorter 4- to 6-week runs are also mentioned, though they may not provide enough time to observe changes. Because human safety data is limited, longer continuous use is not well supported.

Does AOD 9604 need to be injected on an empty stomach?

Many users report injecting in the morning while fasted, about 30 minutes before eating or training. Others split the dose between morning and evening. There is no strong controlled evidence showing that an empty stomach meaningfully changes how the peptide behaves.